Olaparib

FDA Approved: * December 19, 2014
Pharm Company: * ASTRAZENECA PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Olaparib Overview

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.[1] In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA.[2][3][4] The...

Read more Olaparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaparib

Recent Olaparib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Olaparib
  • Capsule: 50mg
  • Tablet: 100mg, 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Olaparib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA